ArticleFrontiers in cell and developmental biology2021
GINS1 Induced Sorafenib Resistance by Promoting Cancer Stem Properties in Human Hepatocellular Cancer Cells.
Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 27 citations in OpenAlex.
- Unraveling the oncogenic and immunomodulatory roles of GINS1: a systematic pan-cancer study.Cancer cell international · 2026Article
- Epicatechin attenuates the stemness of liver cancer stem cells and tumorigenesis through DNA methylation-mediated inactivation of GINS1/HRAS.Journal of translational medicine · 2025Article
- Mechanisms of HRAS regulation of liver hepatocellular carcinoma for prognosis prediction.BMC cancer · 2025Article
- GINS1 facilitates the development of lung adenocarcinoma via Wnt/β-catenin activation.World journal of surgical oncology · 2025Article
- HRAS Induces Ferroptosis through Upregulating HSPB1 in Hepatocellular Carcinoma.Combinatorial chemistry & high throughput screening · 2025Article
- GINS1 is a prognostic biomarker and correlated with methylation and immune escape in liver hepatocellular carcinoma.Frontiers in oncology · 2025Article
- Shared and specific competing endogenous RNAs network mining in four digestive system tumors.Computational and structural biotechnology journal · 2024Article
- [GINS1 Enhances Glycolysis, Proliferation and Metastasis in Lung Adenocarcinoma Cells by Activating the Notch/PI3K/AKT/mTORC1 Signaling Pathway].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Article
- Comprehensive analysis ofTranslational andrology and urology · 2024Article
- OTU deubiquitinase, ubiquitin aldehyde binding 2 (OTUB2) modulates the stemness feature, chemoresistance, and epithelial-mesenchymal transition of colon cancer via regulating GINS complex subunit 1 (GINS1) expression.Cell communication and signaling : CCS · 2024Article
- Machine learning and multi-omics data reveal driver gene-based molecular subtypes in hepatocellular carcinoma for precision treatment.PLoS computational biology · 2024Article
- PAX5 and circ1857 affected DLBCL progression and B-cell proliferation through regulating GINS1.Cancer science · 2023Article
- A novel prognostic biomarker:Translational cancer research · 2023Article
- Overexpression of tousled-like kinase 2 predicts poor prognosis in HBV-related hepatocellular carcinoma patients after radical resection.Frontiers in genetics · 2023Article
- FOXP1-GINS1 axis promotes DLBCL proliferation and directs doxorubicin resistance.Journal of Cancer · 2023Article
- GINS1 promotes the proliferation and migration of glioma cells through USP15-mediated deubiquitination of TOP2A.iScience · 2022Article
- Article
- Identification of MAD2L1 as a Potential Biomarker in Hepatocellular Carcinoma via Comprehensive Bioinformatics Analysis.BioMed research international · 2022Article
- Comprehensive analysis of GINS subunits prognostic value and ceRNA network in sarcoma.Frontiers in cell and developmental biology · 2022Article
- Identification and Validation in a Novel Classification of Helicase Patterns for the Prediction of Tumor Proliferation and Prognosis.Journal of hepatocellular carcinoma · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is characterized by a high rate of incidence and recurrence, and resistance to chemotherapy may aggravate the poor prognosis of HCC patients. Sorafenib resistance is a conundrum to the treatment of advanced/recurrent HCC. Therefore, studies on the molecular pathogenesis of HCC and the resistance to sorafenib are of great interest. Here, we report that GINS1 was highly expressed in HCC tumors, associated with tumor grades, and predicted poor patient survival using Gene Expression Omnibus (GEO) databases exploration. Cell cycle, cell proliferation assay and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.